finanzen.net
03.08.2018 10:55
Bewerten
(0)

Mauna Kea Technologies SA (MKEA-FR): Q2 reveals consignment model is gaining traction

DRUCKEN

goetzpartners securities Limited
Mauna Kea Technologies SA (MKEA-FR): Q2 reveals consignment model is gaining traction

03-Aug-2018 / 09:55 GMT/BST


Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

 

Mauna Kea Technologies SA (MKEA-FR): Q2 reveals consignment model is gaining traction
Recommendation: OUTPERFORM
Target Price: EUR4.10
Current Price: EUR2.80 (COB on 2nd August 2018)

KEY TAKEAWAY

Mauna Kea reported H1/2018 sales of EUR2.7m (-18% YoY) slightly below our expectations, mainly due to delays in revenue recognition from new Cellvizio systems installed under the new consignment business model in the US and a 40% decline in sales in EMEA as a result of increased focus on the core clinical business in the US. Importantly, the company reported strong installed base growth, with the number of new consignment systems installed in H1/2018 (16) already exceeding the number of systems installed in FY2017 (13). As a result, we are revising our sales forecasts for FY2018E and FY2019E. Our estimates for out-year remain broadly unchanged as we continue to believe that Mauna Kea is well-positioned to enter a period of accelerated growth, driven largely by its new pay-per-use business model and continuous improvements in reimbursement for procedures involving Cellvizio. We reiterate both our OUTPERFORM recommendation and EUR4.10 target price.

Q2 results reflect increasing momentum in consignment sales

Sales of EUR1.67m in Q2/2018 were in line with sales of EUR1.69m in Q2/2017 (-1% YoY), but 60% above Q1/2018 sales, suggesting that the company may have reached a turning point as the new consignment model in the US is gaining traction and sales efforts are starting to yield results. This is also reflected in the 4.5-fold increase in new consignment systems placed in Q2/2018 vs. Q2/2017. Consumables sales in Q2/2018 were up 33% vs. Q2/2017, mainly driven by a 60% increase in the US.

Adjusting 2018E - 2019E sales, 2020E and beyond broadly unchanged

In light of reported Q2 sales, we are lowering our FY2018E sales estimate from EUR9.4m to EUR8.3m and FY2019 from EUR11.7m to EUR11.1m to account for delays in the monetisation associated with the consignment business model, as well as to reflect the increased emphasis on the US and Chinese markets compared with EMEA. Due to the lag associated with the new business model, we anticipate revenues on the back of the growth in the Cellvizio installed base in H1/2018 to be realised in H2/2018, and the strong sales efforts and new commercial strategy to start to pay off. This assumes H2/2018E sales of EUR5.6m.

Target price of EUR4.10 suggests 43% upside to current levels

We maintain and reiterate our target price of EUR4.10 per share, which is based on an EV/Sales multiple approach using our EUR25.1m revenue estimate for 2022E, a multiple of 4.0x, a discount rate of 11% and a probability rate of 75%. Our positive stance on Mauna Kea is based on (1) continued improvement in reimbursement structures, (2) growing momentum for sales in key target markets such as the US and APAC, and (3) an expansion of the list of applicable medical specialities. Furthermore, the abundance of complementary technology in targeted therapeutic areas offers upside potential through strategic partnerships. We reiterate our OUTPERFORM recommendation.

Kind regards,


Martin Brunninger | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | martin.brunninger@goetzpartners.com / healthcareresearch@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.


Click here to see our privacy policy.


GPSL has a formal client relationship with Mauna Kea Technologies SA.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach and Thomson Reuters.

If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=3fd7a0da-d112-4828-8222-fd1dc61e9a17&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

 

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

710701  03-Aug-2018 

fncls.ssp?fn=show_t_gif&application_id=710701&application_name=news&site_id=smarthouse

Nachrichten zu MAUNA KEA TECHNOLOGIES Categorie -O-

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu MAUNA KEA TECHNOLOGIES Categorie -O-

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

MAUNA KEA TECHNOLOGIES Categorie -O- Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX klar im Minus -- Dow startet leichter -- Bundesbank zu Konjunktur skeptisch -- Infineon setzt angeblich Chip-Lieferungen an Huawei aus - Unternehmen folgt -- Wirecard, Deutsche Bank im Fokus

Bitcoin hält sich nach Kursturbulenzen bei 8.000 US-Dollar. MorphoSys: Zeitplan für erstes eigenes Medikament bleibt unverändert. Pfeiffer Vacuum und Mehrheitsaktionär Busch kooperieren. QIAGEN-Aktie im Aufwind: US-Zulassung für Molekulartestsystem. Ryanair verdient deutlich weniger. Google schränkt Zusammenarbeit mit Huawei ein.

Die 5 beliebtesten Top-Rankings

Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das höchste Gehalt
Mit welchem Beruf kommt man am ehesten an die Spitze?
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
In diesen Ländern ist Netflix am billigsten
Wo zahlen Abonnenten am wenigsten?
mehr Top Rankings

Umfrage

Die rechtspopulistische FPÖ in Österreich hat für einen Skandal gesorgt. Wie glauben Sie wird sich das auf die Europawahlen auswirken?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Huawei TechnologiesHWEI11
Deutsche Bank AG514000
Daimler AG710000
TeslaA1CX3T
CommerzbankCBK100
BayerBAY001
Amazon906866
NEL ASAA0B733
BASFBASF11
Apple Inc.865985
Infineon AG623100
BMW AG519000
Allianz840400
Volkswagen (VW) AG Vz.766403